Boosting the antimicrobial action of vancomycin formulated in shellac nanoparticles of dual-surface functionality by Al-Obaidy, Saba S.M. et al.
  
Journal of  
Materials Chemistry B          
PAPER 
This journal is © The Royal Society of Chemistry 2018 J. Mater. Chem B., 2018, 00, 1-3 | 1  
 
 
Received 00th January 20xx, 
Accepted 00th January 20xxn 
DOI: 10.1039/x0xx00000x 
rsc.li/materials-b
Boosting the antimicrobial action of vancomycin formulated in 
shellac nanoparticles of dual-surface functionality  
Saba S.M. Al-Obaidy,a,b Ahmed F. Halbus, a,b Gillian M. Greenwaya and Vesselin N. Paunova* 
We report a strong amplification of the antimicrobial action of vancomycin (VCM) encapsulated in shellac nanoparticles 
(NPs) with dual surface functionalisation. These shellac nanocarriers for VCM were produced in  two steps: (i) a pH drop 
from aqueous ammonium shellac solution containing Poloxamer 407 (P407) as a steric stabilising polymer in solution of 
vancomycin hydrochloride, and (ii) subsequent doping with the insoluble cationic surfactant octadecylthrimethylammonium 
bromide (ODTAB) though a solvent change to yield cationic surface functionality. We evaluated the encapsulation efficiency 
of VCM and its release profiles from these nanocarriers. This study explored the antibiotic action of these VCM nanocarriers 
at the various stages of their preparation which helped us to evaluate how they could be made to work efficiently, to adapt 
their design and demonstrate the role of the nanocarrier dual functionalisation on its antibiotic action and delivery. The 
antibiotic effect of VCM loaded in such versatile functionalised shellac nanocarriers was tested on three different proxy 
microorganisms, C. reinhardtii, S. cerevisiae and E. coli. We also compared the antibiotic effect of free VCM with non-coated 
VCM-loaded nanocarriers at the same overall concentrations. The ODTAB coating of the shellac NPs strongly enhanced the 
antibiotic action of the encapsulated VCM across all tested microorganisms. The enhanced VCM action is explained with the 
increased electrostatic adhesion between the ODTAB-coated VCM-loaded shellac NPs and the negatively charged surface of 
the microbial cell walls which allows local delivery of VCM with a high concentration directly on the cell membrane. This 
nanocarrier-mediated boost of the antibiotic action may potentially breathe new life into old antibiotics and help to fight 
off antibiotic resistance by making them more effective. 
 
Introduction 
Vancomycin (VCM) is a glycopeptide antibiotic produced from 
Streptomyces orientalis)1,2 with high activity against Gram-
positive bacteria. It acts by inhibiting the synthesis of the second 
stage of the cell wall, through strong binding to peptides that 
contain D-alanyl-D-alanine at the end of free carboxyl groups.3 
Studies have revealed that VCM also changes the cell 
membrane permeability.4 This antibiotic is usually prescribed to 
treat infections caused by methicillin-resistant Staphylococcus 
aureus MRSA or is given to patients allergic to penicillin or 
cephalosporin.5 It is used largely in intensive care units to treat 
sepsis and hospital infections, as well as for empyema, 
endocarditis, pneumonia cases, soft tissue abscesses and 
osteomyelitis.6-8 Due to its side effects such as phlebitis, 
hypotension, nephrotoxicity, tachycardia, ototoxicity, chills, 
hypersensibility reactions, fever and exanthema make this drug 
is the last resort.6,8-10 It has been used to reduce the infections 
obtained after posterior cervical fusion surgery11 and can 
decrease the occurrence of postsurgical wound infections.12-14  
A number of reports of resistance to VCM has turned 
researchers toward new VCM formulations using nanocarrier 
delivery systems such as nanoparticles and liposomes, which 
offer greater intracellular penetration and the possibility for 
effective intracellular antibacterial action over extended time 
periods.15 Nanocarrier systems have been widely developed in 
the pharmaceutical industry due to their ability to control the 
release of drugs for efficient delivery.16 Recently, formulation of 
biodegradable nanocarriers has attracted much attention 
following concerns about their post-use fate.17,18 Biodegradable 
NPs from renewable natural materials such as lignin, cellulose 
and shellac have a wide range of industrial and pharmaceutical 
applications. Frangville et al.19 developed biodegradable lignin 
nanoparticles which showed no measurable toxicity against 
proxy organisms such as yeast and microalgae. Recently, these 
were applied in a delivery system based on Ag+-loaded lignin 
NPs which were coated with cationic polyelectrolyte.20,21 Al-
Awady et al.22 demonstrated that the antimicrobial action of 
polyelectrolyte-coated NPs alternates with the particle surface 
charge and developed surface-functionalised nanogels for 
encapsulation of antimicrobial 23,24  
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Figure 1. (A) Schematics of the two step process for the preparation of dual functionalised shellac nanocarriers for vancomycin (VCM). The VCM-loaded shellac NPs are sterically 
stabilised with Poloxamer 407 (P407) and have cationic surface functionality achieved by subsequent doping with the cationic surfactant octadecyltrimethyl ammonium bromide 
(ODTAB). (B) Structural formulas of the constituting materials for the preparationon of vancomycin-shellac nanocarriers: P407, ODTAB, VCM and the main components of shellac.  
 
VCM has been loaded within N-trimethyl chitosan (TMC) 
particles for drug delivery applications which had a significant 
antibacterial action against S. aureus with sustained delivery of 
VCM to bone infections.25 Zakeri-Milani et al. enhanced the 
VCM intestinal permeation by loading VCM into (PLGA) 
poly(lactide-co-glycolide) nanoparticles.26 VCM loaded in solid 
lipid nanoparticles adjuvanted with linoleic acid, showed better 
antibacterial activity than free VCM in aqueous solution 
towards both resistant and susceptible bacteria.27 VCM was also 
successfully encapsulated into amino-polysiloxane matrixes 
through a one-step room temperature sol-gel method.28 
Esmaeili et al.29 prepared VCM-loaded MnFe2O4 nanoparticles 
by using a co-precipitation methodand showed that their 
antibacterial activity can be improved by coating them with 
chitosan. Table 1 summarizes some of the characteristics of 
recently reported VCM loaded nanocarriers. In most cases these 
VCM carriers have relatively large particle size and negative 
surface charge which can potentially repel them from with the 
microbial cell membrane. In addition, most studies report VCM 
cytotoxicity prevalently against Gram-positive rather than 
Gram-negative bacteria.  
In this study, we aimed to develop a stable VCM-nanocarrier 
with high efficiency against Gram-negative bacteria, such as E. 
coli, as well as yeast and algal cells. As a nanocarrier material, 
we choose shellac, which is the refined product of the natural 
material Lac secreted by the small parasitic insect Kerria lacca 
on different host trees in South Eastern Asia. It has numerous 
applications in agriculture, food products and enteric coatings 
for tablets,30 lacquers,31,32 dental baseplates,33,34  dental 
varnishes35,36 coating and matrix material,31,37,38 additive in 
foods and cosmetic products, encapsulating agent in 
pharmaceuticals,39-41 as well as a moisture barrier coating.42,43 
Shellac is a complex mixture of polar and non-polar components 
consisting of polyhydroxy acids, lactones and anhydrides,44-46 it 
has a pKa of 6.9 to 7.5 and it is acid resistant,47 being practically 
insoluble in acidic to neutral aqueous medium (pH<7).39,48,49 
Colloidal shellac dispersion have been used for coatings, 
precipitated from alcoholic shellac solution in water.50 Krause 
and Muller51 reported preparation of an aqueous shellac 
dispersion using a high pressure homogenisation technique, 
although their particle size was rather large (5µm). Colloidal 
shellac with particle size 150-300 nm was formulated by Patel 
et al.52 for silibinin encapsulation by using an anti-solvent 
method and xanthan gum as stabilizer. Kraisit et al.53 used 
chitosan as stabilizer to prepare shellac suspensions with size 
range 100-300 nm for encapsulation of bovine serum albumin.  
Here, e developed shellac NPs that could be loaded with VCM, 
and stabilised by using Poloxamer 407 (P407) copolymer to 
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sterically stabilize them. P407 is a non-ionic co-polymer made 
up of poly (ethylene oxide)(PEO)-poly (propylene oxide)(PPO) 
poly (ethylene oxide)(PEO) (see Figure 1B), which is widely used 
in pharmaceutical formulations as a surfactant, solubilizing 
agent, emulsifying and dispersing agent.54,55 We further apply a 
secondary functionalization with a very small amounts of a non-
soluble cationic surfactant, ODTAB to inverse the particle 
surface charge from negative to positive. 
Figure 1A outlines the steps of the VCM encapsulation into the 
shellac nanocarriers and their surface functionalisation. The 
retention of the VCM in the cores is based on hydrophobic and 
electrostatic interactions within the shellac matrix of the 
nanocarrier particles. This steric stabilisation also plays a 
synergistic effect with the cationic surface functionalisation of 
the VCM nanocarrier and can be potentially used in topical/ 
dermal formulation.55 The positive surface charge of the 
ODTAB-coated nanocarrier allows it to adhere electrostatically 
to the microbial cell walls and to deliver locally a high 
concentration of VCM which boost its antibiotic action on 
various types of microbial cells. The loaded VCM within shellac 
NPs allows the antibiotic to be released slowly which mean it 
can potentially be used in wound dressings over longer periods 
of time. The choice of ODTAB as a secondary surface treatment 
allows direct deposition on the shellac NPs surface while the 
already formed sterically stabilizing P407 layer in the first step 
remains intact. This strategy proved very successful, as the 
carrier maintained its steric stability while being surface charge-
reversed by the secondary coating with ODTAB.  
Note that the synthesis of our shellac nanocarrier is a “one pot” 
preparation and allows the cationic antimicrobial or antibiotic 
(e.g. VCM) to be easily encapsulated in the produced 
nanocarrier which amplify its action. Its mechanism of action is 
to deliver high local concentration of antibiotic/antimicrobial 
directly on the microbial cell membrane by electrostatic 
adhesion and to potentially increase its permeability due to the 
presence of both ODTAB and Poloxamer on the nanocarrier 
surface. Similar amplification approaches have been recently 
designed based on cationically functionalized polyacrylic acid 
nanogels loaded with antimicrobials23, 82 as well as inorganic 
antimicrobial particles like CuONPs with grafted phenyl boronic 
acid surface groups which covalently bind to sugar groups on 
the bacteria, thus concentrating the CuONPs on the microbial 
cell membrane and enhancing its antimicrobial effect.83 This 
approach is different to the action of the cationic antimicrobial 
peptides, which act as bacterial membrane disruptors which are 
similar to cationic polyelectrolytes with the advantage of being 
more biocompatible. Recently, however Zhang et al.84 
combined a cationic peptite-fulerene conjugate which showed 
good results in antibacterial photodynamic therapy (PDT) with 
improved efficiency as compared to non-treated fullerene. 
Similarly, the antibacterial effect of the reactive oxygen species 
produced in the PDT are amplified by the cationic peptide which 
“dock” their source on the bacteria surface. Alternative strategy 
has been proposed by Zou et al.85 for photothermal nanodots 
based on self-assembly of peptide−porphyrin conjugates for 
antitumor therapies which may also find antibacterial 
applications.83 Borovicka et al.86-88 combined silica-imprints of 
microbial cells with incorporated gold nanoparticles to produce 
photothermal colloid antibodies for selective laser ablation of 
targeted microorganisms. Interesting approach based on 
imprinting of -lactamase on hydrogel was adopted by Li et al.89 
to treat antibiotic resistant bacteria. The imprinted sites trap β-
lactamase excreted by drug-resistant bacteria, thus making 
bacteria sensitive to antibiotics. Dong et al.90 developed a NIR-
sensitive nanoplatform for synergistic eradication of antibiotic-
resistant bacteria based biofilms both in vitro and in vivo. The 
integration of nanotherapeutics (NO-donor) and antimicrobial 
compounds (quaternary ammonium chitosan) into one system 
could significantly enhance biofilm dispersal as well as prevent 
the recurrence and reduce side effects. 
We studied the antibacterial, anti-fungal and anti-algal action of 
the nanoparticles compared with free VCM on three proxy 
microorganisms, C. reinhardtii, S. cerevisiae and E. coli, 
respectively. We also studied the VCM release kinetics from the 
carrier and the boost of its antimicrobial action before and after 
surface functionalising of the shellac NPs with ODTAB. We show 
that this strategy can strongly amplify the antimicrobial action 
of both VCM compared to solutions with an equivalent 
concentration of free VCM or the non-loaded nanocarrier. 
Materials and Methods 
Materials 
Shellac was used in a soluble form as the ammonium salt at pH 
> 7. The ammonium shellac solution was a gift from (Stroever 
Schellackbremen, Germany) and is commercially available as 
SSB Aqua Gold (solid content 25%). Poloxamer 407 (purified), 
vancomycin hydrochloride (98%), and 3’, 6’-diacetyle 
fluorescein (FDA), were all obtained from Sigma-Aldrich UK. 
Octadecyltrimethyl ammonium bromide (ODTAB) was supplied 
by Fluka Chemika, UK.  Deionised water purified by reverse 
osmosis and ion exchange from a Milli-Q water system 
(Millipore, UK) was used in all our studies. Its surface tension 
was 71.9 mNm-1 at 25°C, with measured resistivity less than 18 
MΩ cm-1. The BacTiter-Glo microbial cell viability assay was 
purchased from Promega, UK. Chlamydomonas reinhardtii (cc-
124 strain) was kindly provided by Flickinger group from North 
Carolina University, USA. This microalgae culture was grown in 
Tris-Acetate-Phosphate (TAP) culture medium and incubated at 
a temperature of 30°C. The C. reinhardtii culture media 
consisted of TAP salts (NH4Cl; MgSO4.7H2O and CaCl2.2H2O), 
phosphate buffer solution (PBS) and Hutner’s trace elements 
solution (EDTA disodium salt, ZnSO4.7H2O, H3BO3, MnCl2.4H2O, 
CoCl2.6H2O, CuSO4.5H2O, FeSO4.7H2O, (NH4)6Mo7O24.4H2O, all 
purchased from Sigma-Aldrich, UK. The microalgae batch was 
grown in the TAP media at pH 7 while being illuminated for 72 
hours with a white luminescent lamp with a light intensity of 60 
W m-2 under constant stirring with a magnetic stirrer.61,62, 63 The 
stock cultures of C. Reinhardtii were with typical concentration 
4  105 cells mL-1 determined by cell counter (Nexcelom 
Cellometer Auto X4) and the E. coli bacterial culture stock was 
with approximately 5  107 cells mL-1. Saccharomyces cerevisiae 
(Baker’s yeast), was purchased from Sigma-Aldrich. It was 
PAPER Journal of Materials Chemistry B 
4 | J. Mater. Chem. B., 2019, 00, 1-3 This journal is © The Royal Society of Chemistry 2019 
 
 
cultured by hydrating 10 mg of lyophilized yeast cells in 10 mL 
of Milli-Q water. Then 1 mL of this hydrated suspension was 
added to 100 mL of autoclaved YPD culture media64 consisting 
of peptone (Sigma Aldrich, UK), D-glucose, (Fisher Scientific, 
UK), and yeast extract, (Oxoid ltd, UK.), then incubated at 30°C 
for 24-48 hours. Escherichia coli, sourced from Thermofisher 
(Invitrogen MAX Efficiency DH10B) was used for our 
antibacterial tests. The cells were cultured in autoclaved Luria-
Bertani medium (LB medium)65 prepared by dissolving 0.5 g 
yeast extract , 0.5 g sodium chloride (Sigma Aldrich), and 1 g 
tryptone (Oxido ltd), in 100 mL water. Fluorescein diacetate 
(FDA, 98%) for cell viability assays was supplied from Sigma 
Aldrich, UK.  
Preparation and functionalization of VCM-loaded shellac NP 
Shellac NPs were prepared by mixing 0.25 w/v% of ammonium 
shellac salt and VCM solution at pH 8 with different 
concentrations of P407 and VCM. 100 mL of this solution was 
prepared, followed by lowering the solution pH to 5 by adding 
drop-wise 0.01 M HCl with a syringe pump at a rate of 220 mL/h 
while agitating with a magnetic stirrer. The concentration of 
VCM was varied in a mixture of shellac and P407 with a constant 
ratio of 0.25 wt%:0.2 wt%, respectively. In order to promote 
their adhesion to the negatively charged microbial cell walls, the 
shellac NPs surface charge was altered from negative (P407-
stabilised shellac NPs loaded with VCM) to positive by an 
additional surface doping with the cationic surfactant ODTAB. 
Typically, 0.07 wt.% of VCM was loaded in 0.25 wt.% shellac NPs 
which were further coated with ODTAB delivered to the shellac 
NP suspension by drop-wise addition from 3% ODTAB in 
ethanol.   
Shellac NPs size, zeta-potential and morphology characterisation  
The particle size and zeta-potential of the shellac NPs with and 
without VCM were measured by dynamic light scattering (DLS) 
using a Zeta sizer Nano ZL (Malvern Instrument Ltd, UK). All 
measurements were carried out in triplicate. Morphological 
examination of the nanoparticles was performed by 
transmission electron microscopy (TEM) (Joel 2010, Japan), a 
few drops of the sample were placed on carbon-coated copper 
grids and negatively stained with 1% aqueous uranyl acetate. 
Once air dried, the sample was imaged with a Gatan Ultrascan 
4000 digital camera attached to Jeol 2010 TEM at 200kV.  
Fourier transform infrared (FTIR) and UV-vis spectroscopy study 
FTIR spectroscopy (Thermo Fisher Scientific Nicolet 380 FT-IR, 
Hemel Hempstead, UK) was used to characterise the shellac NPs 
and VCM-loaded shellac NPs. This technique was also used to 
confirm the adsorption of P407 on shellac NPs surface and the 
intercalation between the VCM and the molecules of the shellac 
matrix. In order to confirm the loading percentage of VCM 
within shellac NPs a UV-Vis spectrophotometry technique was 
used. A sample of VCM-loaded shellac NPs was dissolved in 
alkaline solution (pH 8) and the spectrum was recorded 
between 220-700 nm using the spectrophotometer (model Bio 
Lambda 10, USA). Spectra were also recorded at the same range 
for free VCM and shellac NP coated with P407. The stability of 
VCM encapsulated in shellac nanoparticles was confirmed by 
using FTIR spectra and UV-vis spectroscopy at temperature 25°C 
and 37°C. The VCM-loaded shellac NPs was heated at 37oC for 2 
hours. The VCM-loaded shellac NPs was cooled down to room 
temperature. 
Encapsulation efficiency and VCM loading contents in shellac NPs 
The encapsulation efficiency and the drug loaded content was 
indirectly calculated by measuring the absorptivity of the non-
encapsulated drugs. The non-encapsulated VCM solution was 
filtered using a 20 nm syringe filter and the absorbance of this 
filtered VCM solution was measured at 422 nm using the UV-Vis 
spectrophotometer. A calibration curve of VCM was made by 
measuring the absorbance of a series of standard VCM 
solutions. The VCM loading contents and encapsulation 
efficiency were calculated as shown below66 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
[𝑇𝑜𝑡𝑎𝑙 𝑉𝐶𝑀 − 𝑈𝑛𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 VCM]
[𝑇𝑜𝑡𝑎𝑙 𝑉𝐶𝑀]
× 100 
𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 (%) =
=
[𝑇𝑜𝑡𝑎𝑙 𝑉𝐶𝑀 − 𝑈𝑛𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 VCM] × 100
[(𝑇𝑜𝑡𝑎𝑙 𝑉𝐶𝑀 < −𝑈𝑛𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑉𝐶𝑀) + 𝑠ℎ𝑒𝑙𝑙𝑎𝑐 + 𝑃𝑜𝑙𝑜𝑥𝑎𝑚𝑒𝑟 𝑎𝑚𝑜𝑢𝑛𝑡]
 
In vitro VCM release kinetics from shellac NPs 
The dialysis method was used to determine the in vitro VCM 
release profile from the shellac NPs. 50 mL of the sample 
containing of VCM-loaded shellac NPs were dialyzed (see Figure 
S3, ESI). A dialysis bag of 12-14K MWCO with a pore diameter 
2.5 nm was immersed in a 500 mL buffer phosphate solutions 
(for pH 5.5 and 7.4). The bag was stirred gently with an orbital 
shaker at 37°C temperature and 100 rpm. At specific time 
intervals, 2 mL of the dialysis solution was taken and analysed 
by measuring the UV-vis absorbance from 200-700 nm. 
Measurements were taken in triplicates at 15, 30, 60, 120, 180, 
240, 300, 360 and 1440 min. The cumulative percentage of 
released VCM was calculated using the equation67 
% 𝐼𝑛 𝑉𝑖𝑡𝑟𝑜 𝑉𝐶𝑀 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 =
𝑀𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
𝑀𝑡𝑜𝑡𝑎𝑙
  100,  
where Mreleased is the amount of drug released from the shellac 
NPs at time t and Mtotal is the amount of drug loaded.   
Antimicrobial activity of the non-coated VCM-loaded shellac NPs 
Stock suspensions of VCM-loaded shellac NPs against different 
concentrations of the non-coated and ODTAB-coated VCM-
loaded shellac NPs were incubated with fixed aliquots of the 
microbial cells cultures for different incubation time. The cells 
were removed from their growth media and transferred in Milli-
Q water. Shellac NPs without VCM (as a negative control) and 
free VCM aqueous solution (positive control) was incubated as 
with equivalent cell samples for the same durations. The 
viability of C. reinhardtii and yeast was measured using a cell 
counter after incubating 1 mL of the treated cells (washed from 
the shellac NPs), with 10 L of 0.1 % FDA in acetone for 10 min 
and washing with deionised water by centrifugation. 
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Table 1. Summary of the reported nanocarriers for Vancomycin (VCM) within their characteristics. 
Nanocarrier used to encapsulate VCM Particle size /nm Zeta potential /mV E.E. / %  Drug content / % Reference 
N-trimethyl chitosan (TMC) 220 15 ± 1 74 ± 2 5.8 ± 0.17 56 
Poly vinyl alcohol (PVA) 430±32 
 
26 ± 10 89 ± 2 30 ± 1  57 
Liposome formulation F2 78 -           79 
 
98 58 
Poly vinyl alcohol (PVA) F2 461 ± 33 −7 ± 6 67 ± 2 34 ±2 59 
Polyacrylic acid sodium (PAA) 230 ± 48 −30 ± 5 75 ± 1 58 ± 1 60 
 
The E. coli viability was measured after incubating the cells with 
the VCM-loaded NPs. 100 µL of the treated E. coli suspension 
was washed and mixed with 100 µL of BacTiter-Glo cell 
viability reagent in white opaque 96-well microplate and shaken 
for 5 minutes. The bioluminescence intensity was then 
measured (BMG LABTECH instrument, FLUOstar Omega, 
Germany). 
Protocol for SEM imaging of the treated cell samples 
The cells were washed with Milli-Q water 3 times to remove the 
residual NPs by centrifugation at 3000 rpm for 3 minutes. The 
cell sample was deposited on dry Aclar sheets or poly-lysine 
coated glass coverslips, fixed with 2.5 w/v% glutaraldehyde for 
2 hours, followed by washing with cacodylate buffer.  
 
Table 2: Vancomycin loading content at pH 6 encapsulated with Composition 1 
(0.25 wt% shellac: 0.2wt% P407) and Composition 2 (0.5wt% shellac:0.4wt% P407).  
VCM loaded in shellac 
NPs / mol mL-1 x 10-7 
Drug loading (%) 
 using Composition 1 
Drug loading (%) 
using Composition 2 
6.9  2.33 0.9 
20.7   6.8 3.5 
34.5   10.6 5.8 
48.3 13.6 7.6 
 
The cells were post fixed for 1 hour in 1 wt.% osmium tetroxide, 
washed with a cacodylate buffer, then rinsed with serial 
ethanol-water solutions starting from 50% ethanol  moving up 
to absolute ethanol, then  dried using a critical point dryer. 
Finally, the samples were coated with carbon (~10 nm) in an 
evaporator and imaged using scanning electron microscope 
SEM (ZEISS EVO 60 EP-SEM, Germany).  
 
Cytotoxicity assay of VCM-loaded shellac NPs coated with ODTAB 
on HaCaT cells  
We tested the biocompatibility of our nanocarrier on HaCaT cell 
line culture (immortalized human keratinocytes) which was 
kindly provided by the Skin Research Group at St James 
University Hospital at Leeds. The cells were cultured in high-
glucose DMEM media supplemented with 10% Fetal Bovine 
Serum (FBS, Labtech, UK) and 1% antibiotics (Penicillin 
Streptomycin, Lonza, UK) and placed in an incubator (37°C, 5% 
CO2). After reaching 70% confluence, HaCaT cells were carefully 
washed with PBS for 10 s then incubated with 0.25% Trypsin-
EDTA (1X, Lonza, UK) to detach the cells from their support after 
5 min. Its action was neutralized by adding complete DMEM 
medium before a centrifugation at 400g for 4 min. An 25 mL 
aliquot  of the HaCaT cells culture (~75000 cells mL-1) were 
washed three times from the culture media via centrifuged, and 
re-dispersed with 25 mL PBS. Then, 2.5 mL aliquots of this 
HaCaT cells suspension were incubated with a series of 2.5 mL 
aliquots of aqueous dispersions of VCM-loaded shellac NPs 
coated with ODTAB at different concentrations. Likewise, a 
control sample of the HaCaT cells was treated at the similar 
conditions. After that, 1 mL of the HaCaT suspension was taken 
from each addressed sample with ODTA-coated VCM-loaded 
shellac NPs, washed with PBS to remove the excess of VCM-
loaded shellac NPs coated with ODTAB via centrifuged at 400g 
for 4 min. The HaCaT cells were re-suspended in 1 mL of PBS, 
then two drops of 1 mM FDA solution in acetone was added to 
each sample and mixed together for 15 min followed by triple 
washing with PBS by centrifugation at 400g for 4 min. Finally, a 
microplate reader was utilized to assess the HaCaT cell viability. 
Results and Discussion 
Preparation and characterisation of VCM-loaded shellac NPs 
Figures 2A and 2B and show the particle size distribution and 
the zeta potential of shellac NPs formulated by mixing 0.25 wt.% 
of shellac with 0.2 wt.% P407 at pH 5. This yielded shellac NPs 
of average size of 65 nm and negative zeta-potential of -22 mV. 
Figure 2C shows the dependence of the shellac particle size and 
zeta potential on the pH of the solution. One can see that the 
particle size is insensitive to pH as the shellac particles are 
sterically stabilised, while the zeta-potential is negative due to 
the dissociation of the COOH groups of the shellac constituents. 
Note that ODTAB was not used here to coat the shellac NPs.  
Figure 2D shows the size and the zeta potential of the shellac 
NPs at different concentrations of P407. The size remains fairly 
constant above 0.2 wt.% P407 while the zeta-potential 
decreases slightly due to the offsetting of the surface charge by 
the PEO chains of the attached P407 layers. Figure 2E shows 
that the size of the shellac NPs increased when VCM loading 
concentration increased. The results indicate that shellac NPs 
can be formed with a VCM loading concentration of up to 0.07 
wt. % at 0.25 wt.% shellac. Further increase in the VCM 
concentration resulted in a continuous increase in the particle 
size, starting from ~80 nm at 0.01 wt.% VCM to ~96 nm at 
0.07wt.% VCM. At higher VCM loading concentrations 
aggregation occurs.  
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Figure 2. (A) Particle size and (B) zeta-potential distribution of shellac nanoparticles was obtained by mixing a ratio of 0.25:0.2 wt.% of ammonium shellac: P407 from pH 8 to pH 5 
in deionized water. (C) The shellac NPs average diameter and zeta-potential as a function of the pH of the media. (D) The average diameter and zeta-potential of the non-coated 
non-loaded shellac NPs as a function of the P407 concentration in the initial formulation. (E) The shellac NPs average diameter and zeta-potential as a function of the VCM 
concentration. (F) TEM of ODTAB-coated VCM-loaded shellac NPs; (G) The encapsulation efficiency percent of different concentrations of VCM-loaded shellac NPs at pH 5 and pH 6 
and different shellac and P407 overall concentrations. Compositions 1 and 2 are specified in Table 2. 
The zeta-potential of the VCM-loaded shellac NPs decreased 
slightly with an increase in the VCM loading concentration 
which is probably due to the electrostatic attraction between 
the dissociated carboxylic groups of the shellac constituents and 
the VCM cations. TEM images revealed some of the 
morphological characteristic of VCM-loaded shellac NPs, as 
seen in Figure 2F. The images show that the shape of the shellac 
NPs is spherical with a size less than 100 nm for uncoated shellac 
NPs, which also agrees with the DSL measurements at pH 5 (see 
Figure 2A). We also examined the long term stability of the 
shellac carriers sterically stabilised by P407 over the course of 
90 days by DLS measurements. Figure S1 (ESI) shows that both 
particle size and zeta potential remained stable over this period. 
Figure S2B (ESI) shows the TEM image of the shellac NPs 
suspension sample after drying, and reveals the spherical shape 
of the NPs with a an average size of 33 ± 11 nm as can be seen 
in Figure S2A. This supports the result obtained by using the DLS 
measurements that the shellac particles are consistently 
smaller than 100 nm.  The effect of VCM concentration on the 
encapsulation efficiency was examined indirectly by measuring 
the amount of non-encapsulated VCM (Figure S3A, ESI) using 
VCM standard calibration curve (Figure S3B, ESI). VCM was 
encapsulated with shellac NPs by following the procedure 
described in the previous section. Figure 2G shows that the 
encapsulation efficiency of VCM at pH 5 was low. In order to 
enhance it we varied the pH and the overall amounts of shellac 
and P407. This allowed us to increase the VCM encapsulation 
efficiency from 19% at pH 5 to 88% at pH 6 (Composition 1, see 
Table 2). Doubling the concentrations of shellac and P407 (0.5 
wt.%:0.4 wt.%) (Composition 2, Table 2) increased the VCM 
encapsulation efficiency further, while the VCM loading 
contents within shellac NPs dropped from 13.6% to 7.6% at 48.3 
x 10-7 mol mL-1 VCM. In all experiments throughout VCM was 
encapsulated at pH 6 by using the same Composition 1 of 
shellac and P407 (0.25 wt.%:0.2 wt.%) as it was deemed more 
efficient. 
FTIR and UV-Vis studies 
The FTIR spectra of VCM, shellac NPs, and VCM-loaded shellac 
NPs, are represented in Figure 3A. The FTIR of free VCM (purple 
line) revealed a phenolic OH stretching band at 3261 cm-1, 
stretching aromatic C=C associated with amide I at 1644 cm−1, 
C=O stretching association with secondary amide shows peak at 
1488 cm-1, C-O phenolic, C-N-H amide II, and Ar-O-Ar showed 
peaks at wavenumbers at 1395 cm-1, 1585 cm-1 and 1059 cm-1 
respectively.58,68 Although the shellac NPs and the VCM-shellac 
NPs spectrum (blue line) have a high degree of similarity as VCM 
has similar functional groups (O-H, C=C, and C-H), the small 
shoulders that appear at 1648 cm-1 and 1060 cm-1 for aromatic 
C=O amide and Ar-O-Ar stretching, respectively, belong to VCM 
which indicates its successful encapsulation in shellac NPs.  
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Figure 3. (A) Fourier Transform Infra-Red (FTIR) spectra of free VCM, VCM loaded in shellac NPs with P407, and shellac NP coated with P407 without VCMs; (B) UV-Vis absorption 
spectrum of VCM, free shellac, non-coated VCM-loaded shellac NPs and P407; (C) The percentage of in vitro VCM release as a function of time at different pH. The error bars are 
within the symbol size. 
Some of the P407 peaks overlap with the shellac peaks although 
there is no chemical reaction between shellac and P407. This 
interaction is probably due to the adsorption of the 
hydrophobic part of P407 on shellac surface, and O-H stretching 
band still exist at 3392 cm-1, while the carbonyl stretching 
vibration (C=O) and C-O stretching bands appears at 1711 cm-1 
and 1241 cm-1 respectively. The VCM encapsulation within the 
shellac NPs was also confirmed by using UV-vis spectroscopy. A 
sample of VCM loaded shellac NPs was dissolved in weakly basic 
medium then the absorbance was measured at a range of 200-
500 nm, as well as for free shellac, free VCM and P407. Figure 
3B shows the free VCM spectrum (blue line) with a 
characteristic peak at 280 nm with random peaks between 200-
236 nm. The shellac spectrum also displayed random peaks 
started from 264 nm to 200 nm, whereas P407 does not show a 
specific peak in the UV-vis spectrum. The purple line, which 
represents VCM-shellac NPs, reveals a peak at 304 nm, which 
belongs to VCM but is slightly shifted due to the interaction with 
shellac and random peaks start from 247 nm to 200 nm which 
belong for both shellac and VCM-shellac NPs. This confirms the 
VCM encapsulation within the shellac. 
VCM encapsulation efficiency and release kinetics  
Figure 3C shows VCM release profile from shellac NPs at pH 5.5 
and 7.4 for over 30 hours. This shows that the released 
percentage % of VCM-loaded shellac NPs at pH 5.5 is higher 
than at pH 7.4. For the the first few hours, the release of VCM 
was slow and similar for both pHs, but after 24 hours the release 
increased at pH 5.5 and reached to 48.5% of total VCM amount 
while at pH 7.4 it was only 24%. The high release of VCM at pH 
5.5 can be attributed to the weaker protonation of shellac 
carboxylic groups in acidic media which led to weaker 
electrostatic interactions with the VCM cations released in the 
media. Compared to other studies,68  these shellac NPs loaded 
VCM showed a sustained release over longer periods of time.  
We also tested the stability of the VCM-loaded shellac 
nanocarrier system at two different temperatures, 25 C and 37 
C for up to 6 hours of incubation. Figure S9 shows the UV-Vis 
spectra of the VCM-loaded nanocarrier after incubation at 37 C 
which show no significant change. 
Cationic surface functionalisation of shellac NPs 
Figure 4 shows that size and zeta-potential distribution of the 
ODTAB-coated VCM loaded shellac NPs. One sees that the 
surface charge can been reversed by adding different amounts 
of ODTAB in ethanol solution after the preparation of the 
shellac NPs (at pH 5.5). Figure 4C shows that the zeta potential 
of VCM-loaded shellac NPs decreased with the increase of the 
concentration of added ODTAB. 0.07 wt.% ODTAB was 
considered to be the optimal amount to coat 0.05 wt.% VCM-
loaded shellac NPs with zeta potential of +10 mV and ~98 nm 
mean diameter. Morphological characterisation of these 
particles using scanning electron microscopy revealed that they 
have a spherical shape and an average size consistent with that 
obtained from the DLS measurements (see Figure 4D).  
The toxicity effect of the non-loaded shellac NPs  
To check whether the loading of VCM within the shellac 
nanoparticles could enhance the antibacterial activity of VCM, 
a blank experiment was carried out first where the cytotoxic 
effect of the empty (non-loaded) shellac nanocarrier, was 
studied on three different types of cells: microalgae, yeast and 
bacteria.  
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Figure 4. (A) Particle size and (B) zeta-potential distribution of shellac nanoparticles of 0.05 wt. % VCM loaded Shellac NPs after coating with 0.07 wt. % of ODTAB at pH 5.5. (C) The 
effect of coating of 0.05 wt.% VCM-loaded shellac NPs with different concentrations of ODTAB on the size and zeta potential at pH 5. (D) Scanning electron microscopy image of 0.05 
wt. % of VCM NPs after coating with 0.07 wt. % of ODTAB. 
 
The live/dead assay for shellac NPs was determined by 
incubation of the cells with shellac NPs suspensions of different 
shellac concentrations produced by serial dilutions of more 
concentrated stock. The cells were removed from the culture 
media to avoid any interaction between shellac NPs and media 
components. Figure 5 shows the cytotoxic effect of shellac NPs 
without VCM on C. reinhardtii, S. cerevisiae and E. coli, 
respectively. As it can be seen from Figure 4A, there is a small 
cytotoxic effect of shellac NPs on the algal cells at relatively high 
concentration due to the P407, which was used as a stabilizer. 
It has been previously reported that P407 might create a 
adsorption layer on the microbial cell surface,69-71 so the 
combination between P407 and the shellac NPs may play a 
synergistic antimicrobial role within this nanocarrier design. The 
shellac NPs, however, showed no pronounced effect when 
incubated with yeast and E.coli for 6 hours, as demonstrated in 
Figures 5B and 5C. One possible explanation for the lack of 
effect on yeast is that its cells have much a thicker cell wall 
which mitigates the effect of P407 at these concentrations. For 
all cell types studied, lower concentration of the shellac NPs are 
benign over the duration of the experiment (4 hours). At this 
concentration of nanocarriers we were able to evaluate the 
effect of the VCM – see below. 
Antimicrobial activity of VCM-loaded shellac NPs 
We compared the antimicrobial activity of free VCM and VCM-
loaded shellac NPs (non-coated) on the same microbial cultures, 
C. reinhardtii, S. cerevisiae and E. coli in order to determine 
whether the loading of VCM within shellac NPs could enhance 
its antimicrobial activity. The purpose of encapsulating VCM 
within shellac NPs was to increase its antibiotic action.  It was 
anticipated that the increased surface area of the nanocarrier, 
would result in the need for less VCM, thus reducing the 
potential side effects of the VCM and making it more 
bioavailable in medical formulations increasing its efficacy.72-76 
However, our experiments showed that the VCM encapsulation 
in the shellac nanocarriers generally lowered its efficiency.  
Fig. S4 shows the cell viability of the C. reinhardtii as a function 
of the concentration of free VCM. The antialgal activities of free 
VCM and VCM-loaded shellac NPs were studied on microalgae 
at different incubation times and at room temperature to 
examine their effects on C. reinhardtii as presented in Figures 
S4A and S4B (ESI). The algae cells were incubated with solutions 
of various concentrations of free VCM up to 0.1 wt.%. At the 
highest VCM concentration, the algal cell viability steadily 
declined to about 50% after 6 hours of incubation. Figure S4B 
shows that VCM showed lower activity after loading it within 
shellac NPs compared with free VCM at the same concentration 
and incubation time. After 4 hours incubation of the cells with 
different concentrations of VCM-loaded shellac NPs, their 
viability did decrease slightly by about 10% at 0.05 wt.% of VCM. 
After 6 hours, the cell viability dropped by 15-20 %. The reason 
why the antimicrobial activity decreased after loading VCM 
within shellac NPs is because of the repulsion between 
negatively charged shellac NPs and the negatively charged algal 
cell membrane which repels the nanocarrier and does not allow 
VCM to be released in its immediate vicinity. This impairs the 
effect of the nanocarrier. The SEM images of C. reinhardtii cells 
in Figure S4E and S4F show that the free VCM caused damage 
to the cell membranes whereby cells have shrunk and appear 
wrinkled in comparison with control sample as shown in Figure 
S4C and S4D. In comparison, the effect of the VCM-loaded 
shellac NPs on the cell membrane of algae seems less 
pronounced as in Figures S4G and S4H (see ESI). The antifungal 
activity of free VCM and VCM loaded shellac NPs were studied 
on S. cerevisiae cells at different concentrations at pH 5.5 using 
the FDA live/dead assay. Figure S5A and S5B show the effect of 
free VCM and VCM loaded NPs on S. cerevisiae at a range of 
incubation times.  
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Figure 5. The effect of the P407 stabilised non-loaded shellac NPs on the viability of (A) C. reinhardtii, (B) S. cerevisiae and (C) E. coli cells incubated with different concentrations of 
shellac NPs (made from fixed ratio of 0.25 wt.% ammonium shellac and 0.2 wt.% P407) at different incubation times. The ratios on the x-axis show the actual concentrations of both 
shellac and P407. No VCM was used in these experiments. Here the shellac NP were stabilised by P407 but not coated with ODTAB. 
 
Figure S5A shows that free VCM had weak effect on the yeast 
cells although some effect was seen at high concentrations of 
free VCM. At 0.1, 0.15 and 0.25 wt.% of VCM the cell viability 
decreased from 97% for the control (no VCM) to 70%, 62%, and 
58% respectively after 4 hours of incubation. After 6 hours of 
exposure to VCM, the cell viability declined slightly from 98% at 
control to be 62%, 54% and 45% at (0.1, 0.15, and 0.25) wt. %, 
respectively. At shorter incubation times the VCM effect was 
negligible. Loading the VCM within shellac NPs was seen to 
reduce its anti-yeast effect as shown in Figure S5B. The VCM-
loaded shellac NPs showed very low activity toward the yeast 
cells due to the repulsion between the NPs and cell wall. The 
SEM images of yeast cells after being incubated for 4 hours with 
0.01 wt.% of free VCM (Figure S5E and S5F) and VCM loaded 
shellac NPs (Figure S5G and S5H), show that they both did not 
have a visible effect on the yeast cells membranes in 
comparison with the control (Figure S5C and S5D) at these 
concentrations. This indicates that the non-coated VCM-loaded 
shellac NPs are ineffective against yeast.The antibacterial 
activity of free VCM and VCM-loaded shellac NPs was compared 
after incubating E.coli with different concentrations of free VCM 
and measuring the cell viability by by using BacTiter-Glo 
luciferase assay. Figure S6A shows the effect of free VCM at 
different exposure times. Note that even at longer times the 
VCM showed medium antibacterial activity, possibly as it is 
more effective as Gram-positive antibacterial agent and due to 
its large size that can hardly penetrates the cell walls of Gram-
negative bacteria.77,78  
We found that the antibacterial effect of the VCM-loaded in 
shellac NPs was even smaller than that of free VCM as shown in 
Figure S6B. After 4 hours of exposure, the cell viability declined 
by about 20% at (0.0005, 0.001, and 0.005) wt.% of total VCM 
concentration and reduced by about 50% at 0.025 wt.% of VCM 
after 6 hours. Figures S6E and S6F (ESI) show the SEM images of 
E.coli cells incubated with 0.01 wt.% of free VCM and VCM 
loaded shellac NPs (Figures S6G and S6H) in comparison with 
control (Figures S6C and S6D). Although one can see some very 
low degree of deposition of NPs on the E.coli cell membranes in 
Figure S6G and their wrinkling in Figure S6H the effect does not 
seem to correlate directly with the cell viability (Figure S6B), 
which is higher than the one for free VCM (Figure S6A). As with 
algae and yeast, one can conclude that the encapsulation of the 
VCM in the shellac nanocarrier does not give immediate 
advantages over the use of free VCM at the same total 
concentration. We attribute this to the lack of adhesion of the 
non-coated nanocarriers to the microbial cell membranes. 
Cationic surface functionalised shellac nanocarriers  
In order to reverse the negative surface charge of the shellac 
NPs, we coated them  with ODTAB which was added from 
ethanol solution. ODTAB is a cationic surfactant but it is 
practically insoluble in water at room temperature. Although 
cationic surfactants have moderate toxicity, after coating on the 
nanocarrier surface with ODTAB, it has very limited antibacterial 
effect on the E. coli cell viability (Figure S7). Figure S8 shows the 
SEM images of the three types of microbial cells incubated with 
non-loaded ODTAB-coated shellac NPs. One can see that there 
is a significant accumulation of the ODTAB-coated nanocarrier 
particles on the surface of the cell walls for C. reinhardtii 
(Figures S8A and S8B) and E.coli (Figures S8E and S8F). Yeast 
cells (Figures S8C and S8D) clearly show changes on their cell 
wall morphology, but no ODTAB-coated nanocarrier particles 
have remained attached after the SEM sample preparation.  
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Figure 6. (A) The viability of C. reinhardtii upon incubation at pH 5.5 with aqueous solutions of different concentrations of VCM encapsulated in ODTAB-coated shellac NPs. The 
solutions were prepared from 0.05 wt.% VCM-loaded shellac NPs coated with 0.07 wt.% ODTAB stock solution. (B) The C. reinhardtii viability upon incubation with 0.001 wt.% 
encapsulated VCM in shellac NPs, 0.001 wt.% free VCM, 0.005 wt.% shellac NPs coated with 0.001 wt.% ODTAB, 0.001 wt.% VCM-loaded in shellac NPs coated with 0.0014 wt.% 
ODTAB, and 0.001 wt.% pure ODTAB at pH 5.5 and at room temperature. (C)-(F) SEM images of C. reinhardtii whereby (C) represent the control sample, (D)-(F) sample incubated 
with 0.001 wt.% VCM-loaded shellac NPs coated with 0.0014 wt. % ODTAB after 2 hours incubation at room temperature.  
 
One may draw comparison with Figures S5E and S5F where the 
shellac nanocarrier is not charged positively. One possible 
explanation for the different result for yeast is that the cell wall 
is not sufficiently charged for strong electrostatic adhesion to 
retain the particles during the SEM sample preparation. 
Antimicrobial effect of ODTAB-coated VCM-loaded shellac NPs  
The anti-algal activity of ODTAB-coated VCM-loaded shellac NPs 
was studied by incubating C. reinhardtii at different overall 
concentrations of VCM (Figure 6A).After only 15 min of 
incubation, the cell viability of microalgae decreased sharply 
from 92% for the control sample to (25, 18.5, 14, and 8.5)% at 
(0.003, 0.005, 0.007, and 0.01) wt.% VCM-loaded shellac NPs 
coated with ODTAB. After 2 hours the cell viability of C. 
reinhardtii continued to decrease to (9.5, 7, and 2.5) % at (0.005, 
0.007, and 0.01) wt.%, VCM-loaded in shellac NPs coated with 
ODTAB. The effect is much stronger than the anti-algal effect of 
the same concentration of VCM, i.e. after coating with ODTAB, 
the VCM-loaded nanocarrier increased its anti-algal action. 
Figure 6B compares the  anti-algal activities of 0.001 wt.% VCM-
loaded in shellac NPs, 0.001 wt.% free VCM, 0.005 wt.% shellac 
NPs coated with 0.001 wt.% ODTAB without VCM and 0.001 
wt.% VCM-loaded shellac NPs coated with 0.0014 wt.% ODTAB.  
There is a clear change in the anti-algal action of VCM after 
coating it with ODTAB. Scanning electron microscopy images of 
algal cell after incubated with 0.01 wt.% VCM-loaded shellac 
NPs coated with 0.014 wt.% ODTAB for 2 hours can be seen in 
Figure 6D-6F. The SEM images show that the VCM-loaded NPs 
accumulate around the cell wall in abundance; this attraction 
allows the NPs to release VCM directly on the cell membrane 
which effectively kill them as shown in Figure 6B. The anti-yeast 
effect of the VCM-loaded shellac NPs coated with ODTAB was 
examined by incubating culture media free yeast cells at 
different overall concentrations of VCM at different incubation 
time. Figure 7A shows the yeast cell viability upon incubation 
with different concentrations of VCM loaded shellac NPs coated 
with ODTAB for 15 minutes. The cell viability steeply decreased 
from 94% for the control to 38%, 32%, 3.3% and 2.8% at (0.0005, 
0.001, 0.003 and 0.005) wt.% of VCM-loaded in shellac NPs 
coated with (0.0007, 0.0014, 0.0042, and 0.007) wt.% ODTAB, 
respectively. These suspensions were produced by gradual 
dilution of more concentrated stock. Figure 7B compares the 
anti-yeast actions of 0.005 wt.% VCM-loaded in shellac NPs, 
0.005 wt.% free VCM, 0.025 wt.% shellac NPs coated with 0.007 
wt.% ODTAB (no VCM) and 0.005 wt.% VCM-loaded in shellac 
NPs coated with 0.007 wt.% ODTAB. One can see that using 
ODTAB to change the surface charge of the NPs from negative 
to positive significantly increased the anti-yeast action of the 
VCM in the nanocarrier. Figure 7 shows SEM images of yeast 
cells incubated with 0.01 wt.% VCM-loaded in shellac NPs 
coated with 0.014 wt.%. ODTAB. The coated shellac NPs also 
showed antimicrobial effect due to the positive surface charge 
which synergistically increase the effect of the VCM.  
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Figure 7. (A) The viability of S. cerevisiae upon incubation at pH 5.5 with different amounts of VCM-loaded shellac NPs coated with ODTAB at room temperature at different incubation 
time. The solutions were prepared from 0.05 wt.% VCM (shellac) NPs stock solution coated with 0.05 wt.% ODTAB. (B) The yeast cells viability upon incubation with 0.005 wt.% VCM-
loaded shellac NPs, 0.005 wt.% free VCM, 0.025 wt.% shellac NPs coated with 0.007 wt.% ODTAB, 0.005 wt.% VCM-(shellac NPs) coated with 0.007 wt.% ODTAB. (C)-(H) SEM images 
of S. cerevisiae whereby (C) represents the control sample, (D)-(F) S. cerevisiae incubated with 0.005 wt.% VCM-loaded in shellac NPs coated 0.007 wt. % ODTAB after 2 hours 
incubation time at room temperature.  
 
Note that free VCM or non-coated VCM-loaded shellac NPs 
were ineffective against yeast (cf. Figure S5, ESI). Figure 8A 
shows the antibacterial activity of different concentrations of 
VCM-loaded shellac NPs after coating with cationic electrolyte 
ODTAB to change the surface charge from negative to positive 
at pH 5.5. After 15 minutes of incubation the VCM-loaded 
shellac NPs coated with ODTAB showed little effect on the 
bacteria at concentrations of 0.0001, 0.0005, and 0.001 wt.%, 
coated with 0.00017, 0.0008, and 0.0017 wt.% ODTAB, but at 
higher concentration of  0.01 wt.% VCM-loaded in shellac NPs 
coated with ODTAB the cell viability decreased sharply from 40 
 105 RLU at control to 0.8  105 RLU. After 1 hour, most cells 
died at 0.01wt.% VCM-loaded in shellac NPs coated with 
ODTAB, while the cell viability represented by luminescence 
declined from 39  105 RLU as control to be 29, 22 and 17  105 
RLU at (0.0001, 0.0005, and 0.001) wt.%  VCM-loaded shellac 
NPs coated with 0.00017, 0.0008, and 0.0017 wt.% ODTAB, 
respectively. After 2 hours of incubation the cell viability 
dropped from 39  105 RLU to (20, 18, and 7)  105 RLU at 
(0.001, 0.0005, and 0.001) wt.% VCM-loaded shellac NPs coated 
with ODTAB, respectively. Figure 8B shows the comparison 
between free, uncoated and coated VCM-loaded shellac NPs. 
The uncoated VCM-loaded shellac NPs showed less toxicity than 
the free VCM and both had an unnoticeable effect on E.coli after 
1 hour of incubation, whereas, shellac NPs coated with ODTAB 
had an effect on the cell viability after 1 hour incubation due to 
the positive surface charge. Scanning electron microscopy 
images of E.coli incubated with 0.01 wt.% VCM loaded in shellac 
NPs coated with 0.014 wt.% ODTAB after 2 hours incubation can 
be seen in Figure 8D-8F. These images indicate that VCM-loaded 
ODTAB-coated shellac NPs attach to the cell's membrane. On 
the other hand, free VCM did not show noticeable cytotoxic 
effect when incubated with the same microorganisms, even at 
high concentrations, as well as when it encapsulated within 
non-coated shellac NPs. The reasons behind this are that VCM 
is a bulky molecule and it expresses better antibiotic against 
Gram-positive rather than Gram-negative bacteria. When VCM 
is loaded within bare shellac NPs an electrostatic repulsion 
occurs between these NPs and the cell membranes as both have 
negative surface charge. However, upon coating with ODTAB, 
the nanocarrier surface charge changes to positive which 
promotes its adhesion to the cell wall and the cytotoxic action 
of the loaded VCM was increases significantly. 
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Figure 8. (A) The antibacterial activity of different concentrations of VCM-loaded shellac NPs coated with ODTAB against E.coli. These solutions were prepared from 0.03 wt.% VCM 
loaded shellac NPs coated with 0.05 wt.% ODTAB as stock solution. (B) The relative luminescence unit representing the E.coli viability upon incubation with 0.01 wt.% VCM loaded 
in shellac NPs coated with 0.014 wt.% ODTAB in comparison with the antibacterial activity of free VCM and VCM-loaded shellac NPs and the cytotoxic effect of ODTAB-coated shellac 
NPs. The incubation was also achieved through incubating each concentration with a fixed amount of E.coli at pH 5.5. The data on (A) and (B) represent the luminance of the samples 
after treatment with BacTiter-Glo reagent which is proportional to the concentration of viable bacteria (C)-(F) SEM images of E. coli cells whereby (C) represent the control sample, 
(D)-(F) E.coli incubated with 0.01 wt.% VCM-loaded in shellac NPs coated with 0.014 wt. % ODTAB after 2 hours incubation time. 
 
This type of enhanced antibiotic action can potentially work 
even to resistant microorganisms by overwhelming their 
defence mechanisms, e.g. efflux pumps and cell wall 
permeability. Since VCM is ineffective to Gram-negative 
bacteria due to their complex cell wall, one can conclude that 
the dual functionalisation of the carrier not only delivers high 
local concentration of VCM on the bacterial cell wall but also 
contributes towards compromising its permeability – c.f. Figure 
8B for the effect of free VCM and VCM-loaded in shellac NP 
coated with ODTAB. Since the Poloxamer 407 coating has low 
toxicity towards E.coli, the likely effect comes from the cationic 
nature of the nanocarrier. The antimicrobial effect of the shellac 
NPs encapsulated VCM coated with ODTAB follow the order: 
yeast > algae > E.coli. Other studies have also indicated that 
VCM, when loaded on a nanocarrier can express cytotoxic effect 
on E.coli.79,80 On the other hand, their study80 showed that the 
minimum inhibition concentration of  nanocarrier-loaded VCM 
on E.coli was >1.28 mg mL-1, while our formulation showed that 
minimum inhibition concentration of the shellac-encapsulated 
VCM coated with ODTAB was 0.01 mg mL-1. Most published 
work on VCM-loaded nanocarriers studied its action against 
Gram-positive bacteria, and no previous work has reported on 
its action against microalgae or yeast. In both cases, the 
cytotoxicity of VCM increased when loaded within shellac NPs 
and coated with ODTAB due to the positive surface charge of 
the nanocarrier surface which promotes the adhesion of these 
nanocarriers with the cell membrane.  
Cytotoxicity of the ODTAB-coated VCM-loaded shellac NPs on 
human cells 
Figure 9 shows the cytotoxicity assay of the ODTAB-coated 
VCM-loaded shellac NPs on HaCaT cells for up to 24 h of 
exposure. Both runs were done at the varying overall VCM 
concentration and different incubation times. One can see a 
very small effect on the presence of ODTAB-coated VCM-loaded 
shellac NPs on the cells viability over a period of up to 24 hours. 
Note that the control sample of HaCaT cells have lost a minor 
fraction of their viability over this period of time due to 
depletion of the culture media. One can conclude that the 
nanocarrier does not measurably impact the cell viability up to 
0.07 M VCM. However, at these concentrations of VCM-loaded 
in the shellac nanocarrier, the effect on algae, yeast and E.coli 
is very significant – see Figure 6, 7 and 8, respectively. 
Therefore, one may conclude that the shellac nanocarrier 
shows excellent biocompatibility with these human skin cell 
line. More research will be conducted in the future on the 
effects of the nanocarrier on different type of other cell lines. 
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Figure 9. HaCaT cell viability after incubation as a function of nanoparticle 
concentration for up to 24 hours at with free VCM and ODTAB-coated VCM-loaded 
shellac NPs.” 
Conclusions and outlook 
We have designed and developed a universal and very efficient 
nanocarrier for vancomycin which is based on shellac, a natural 
and biodegradable material. The nanocarrier was formulated 
and loaded with antimicrobial agent in two steps: (i) The first 
step involved controlled precipitation of aqueous ammonium 
shellac salts by a simultaneous pH change from 8 to 5 and 
adsorption of surface active polymer (P407) in the presence of 
the VCM. In this step, the VCM-loaded shellac NPs were formed 
spontaneously and simultaneously coated with a sterically 
stabilizing P407 polymer, which allowed them to maintain their 
stability and ensure long shelf-life. Stable shellac NPs were 
produced at pH 5 with a particle average hydrodynamic 
diameter of 66±5 nm with zeta potential –18±8 mV. (ii) The 
second step in the nanocarrier fabrication involved charge-
reversing of the produced shellac NPs by doping their surface 
with an insoluble cationic surfactant (ODTAB), which gave them 
a positive surface charge in order to promote the nanocarrier 
adhesion to the negatively charged cell membranes of typical 
bacterial cells. Note that this was achieved without 
compromising the P407 steric stabilisation. Optimal nanocarrier 
stability was obtained at a fixed concentration ratio of 0.25 wt.% 
: 0.2 wt.% of shellac : P407. Using 0.01 - 0.07 wt.% concentration 
range of VCM with 0.25 wt.% shellac at pH 5 to be encapsulated 
within shellac NPs we achieved maximum encapsulation 
efficiencies of 87% for VCM at pH 6. The interaction between 
the NPs and the antimicrobials was characterized using FTIR and 
UV-visible techniques. We studied the release profiles of VCM 
loaded into the shellac nanocarriers and characterised the 
effect of the VCM-loading on their size and zeta-potential.   
In this study we systematically examined the importance of the 
nanocarrier architecture on the antimicrobial activity of the 
loaded VCM. We studied the antimicrobial activity of VCM-
loaded shellac nanocarriers on microalgae, yeast and bacterial 
cells. Despite free VCM having moderate antimicrobial effect on 
algae, yeast and Gram-negative bacteria as E. coli, the non-
coated shellac nanocarriers with VCM showed a reduction in 
the antimicrobial activity. This was attributed to the 
electrostatic repulsion between the negatively charged shellac 
NPs and the negatively charged microbial cell membranes 
which did not allow the loaded VCM to be released in vicinity of 
the microbial cell wall. This was exacerbated by the attraction 
between the VCM cations and the shellac matrix of the 
nanocarriers which slowly releases the VCM. Upon ODTAB 
surface functionalisation of the VCM-loaded shellac NPs, their 
surface charge changed from negative to positive. We found the 
optimal conditions where the functionalised shellac 
nanocarriers become cationic and still maintained their stability 
due to steric interactions of the P407 layer. We demonstrate 
that the antimicrobial activity of these ODTAB-coated shellac 
NPs loaded with VCM increased very significantly the 
antimicrobial effect of VCM compared with an equivalent 
overall concentration free VCM in the solution. This effect was 
due to the strong electrostatic adhesion with the cell membrane 
which allowed the VCM to be released directly into the 
microbial cell walls. This type of versatile surface-functionalised 
shellac nanocarriers can be potentially applied to boost the 
action for a range of topical antibiotics which may boost their 
antibiotic action and could be used across different therapies to 
fight antimicrobial resistance. 
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